Home

OrbiMed Asia GP IV, L.P.

CIK 1966836 · last filed 2024-04-05

OrbiMed Asia GP IV, L.P. is a corporate insider who has filed 2 SEC Form 4 insider transactions across 1 company since 2023. The firm reports its address in Grand Cayman, E9. 7 SEC filings were submitted jointly with OrbiMed Advisors IV Ltd.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

1

Total Filings

2

Lifetime Open-Market Net

$0

Filer Profile

Reported Address
190 ELGIN AVENUE
GEORGE TOWN
GRAND CAYMAN, E9 KY1-9001
Phone
(212) 739-6400
State of Incorporation
Cayman Islands
Related Filers
OrbiMed Advisors IV Ltd — 7 joint filings, latest 2024-04-05
OrbiMed Capital GP VIII LLC — 7 joint filings, latest 2024-04-05
ORBIMED ADVISORS LLC — 6 joint filings, latest 2024-04-05
ORBIMED CAPITAL LLC — 4 joint filings, latest 2024-04-05
OrbiMed Capital GP VII LLC — 4 joint filings, latest 2024-04-05
OrbiMed Genesis GP LLC — 4 joint filings, latest 2024-04-05
325 Capital Master Fund LP — same reported address
Apollo S3 Advisors, L.P. — same reported address
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Kinnate Biopharma Inc. (KNTE) Delisted Director 550,000 $2.65 $1.46M $0 1 2023-02-23

Recent Filings

2 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2024-04-05 — Disp (D) −56,068,103 $0
2023-02-23 Kinnate Biopharma Inc. (KNTE) Delisted Grant (A) +7,700,000 $0 EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.